Navigation Links
Pipeline for Lung Cancer Therapies is Focus of New MedPredict Report
Date:2/19/2008

SCOTTSDALE, Ariz., Feb. 19 /PRNewswire/ -- MedPredict has published a new report in its oncology series entitled "Thought Leader Insight & Analysis: Lung Cancer," designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in non-small cell and small cell lung cancer.

Lung cancer continues to be the leading worldwide cause of cancer death. Researchers are pursuing a broad array of mechanistic approaches to treatment, including angiogenics/VEGF, EGFR resistance (T790M, MET), HER2 (ErbB2), antifolate, anti-microtubule, apoptosis, Bcl-2/Bcl-xL, TRAIL, vascular disrupting agents, Ras, Raf, MEK, mTOR, PI3, AKT, IGF-1, HSP90, HDAC, JAK/STAT, MAGE-A3, CDK, Aurora Kinase, and anticoagulation.

MedPredict conducted primary, qualitative interviews with renowned US-based Thought Leaders in the areas of non-small cell and small cell lung cancer in order to identify the most promising candidates in clinical development, as well as explore unmet needs. "This report will provide essential strategic insight for those involved in development of lung cancer therapies," according to MedPredict President Dr. Jeffrey Berk. "Our Thought Leader Panel discusses ongoing clinical programs, and offers their opinions on which of the myriad new drugs in development are likely to be significant improvements over current options."

Some of the companies/partnerships discussed in this report include: Genentech/Roche, Pfizer, AstraZeneca, GlaxoSmithKline, Onyx/Bayer-Schering, Regeneron/Sanofi-Aventis, Genentech/OSI, Imclone/BMS/Merck Serono, Lilly, Exelixis, Wyeth, Boehringer-Ingelheim, Novartis, Mitsubishi/Aveo, Cell Therapeutics, Abbott/Genentech, Genentech/Amgen, Antisoma/Novartis, Antigenics, Concordia, Prolexys, Critical Outcome Technologies, Merck, Schering-Plough, Infinity/Medimmune/AstraZeneca, Synta, Serenex, Bristol Myers Squibb, Abbott, Millennium, Vertex/Merck, Cyclacel.

The full report can be purchased by contacting MedPredict.

About MedPredict

MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
2. Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations
3. Progen Expands Drug Development Pipeline Through Acquisition of CellGate
4. Monsantos R&D Pipeline Set to Deliver Valuable Products to Farmers Well Into Next Decade
5. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
6. Lighting the Onco-Pipeline, Stem Cell Cancer, and More at Global Cancer Congress, January 28-29, 2008, Tampa
7. Michigan Life Sciences Pipeline to Kick Off MichBio Expo
8. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
9. More than $6 Million Raised During Two-Day Event to Support Research and Treatment for Childhood Cancer and Other Catastrophic Diseases
10. Accelerated Community Oncology Research Network, Inc. (ACORN), Initiates a Phase 2b Metastatic Breast Cancer Trial in Cooperation With Bayer and Onyx
11. New Technology for Early Detection of Lung Cancer Selected for Clinical Study With Veterans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives of the ... for Excellence in Volunteer Experience from US2020. , US2020’s mission is to change ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
(Date:10/9/2017)...  BioTech Holdings announced today identification and patenting ... stem cell therapy prevents limb loss in animal ... that treatment with ProCell resulted in more than ... to standard bone marrow stem cell administration.  Interestingly, ... of therapeutic effect.  ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 No two people are ... the New York University Tandon School of Engineering ... found that partial similarities between prints are common ... mobile phones and other electronic devices can be ... vulnerability lies in the fact that fingerprint-based authentication ...
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
Breaking Biology News(10 mins):